Oral Rinse to Reduced Expelled Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) During COVID-19 Infection

January 28, 2026 updated by: Yingda L Xie, Rutgers, The State University of New Jersey

Effect of Oral Hygiene Products on Reducing Expelled/Exhaled SARS-CoV-2

Prospective, cross-sectional study evaluating the effect of commercially available mouthwashes on expelled/exhaled SARS-CoV-2 viral load using face mask sampling.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

The study will consist of a Control Phase to optimize procedures for measuring expelled/exhaled viral load, and a Evaluation phase comparing different commercially available mouthwashes.

In the Control Phase. up to 20 COVID-19 patients will be asked to undergo a sequence of face mask sampling and saliva collections prior to and after an oral rinse with (i) water and (ii) a commercially-available cetylpyridinium chloride (CPC) mouthwash.

Based on outcomes of the Control Phase, the study will proceed into the Evaluation Phase, which will randomize approximately 40 COVID-19 patients to receive 1 of 4 commercially available Colgate mouthwashes following standard package instructions. Face mask sampling and saliva will be collected prior to and after the mouth rinse to assess impact on SARS-CoV-2 viral load.

Study Type

Interventional

Enrollment (Actual)

34

Phase

  • Early Phase 1

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • New Jersey
      • Newark, New Jersey, United States, 07103
        • University Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  1. Age ≥ 18
  2. Able to provide consent
  3. Polymerase chain reaction (PCR)-confirmed SARS-CoV-2 within previous 48 hours.

Exclusion Criteria:

  1. Clinical contraindication or poor feasibility to complete study procedures
  2. Unwilling or unable to produce saliva or face mask samples
  3. Unable to produce at least 500 microliters of saliva.
  4. Eaten within past 30 minutes
  5. Known allergy to mouthwash products

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: N/A
  • Interventional Model: Sequential Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: 0.075% Cetylpyridinium Chloride
Crossover design where a series of viral load measurements are taken before and after water rinse (placebo) and repeated before and after CPC rinse (intervention). The order of the rinses were randomized after the 19th participant.
Commercially over-the-counter Colgate mouthwashes will be administered according to standard package instructions. Viral load will be measured prior to and after mouth rinse using serial face mask and saliva samples. Additionally viral load measured prior to and after water rinse using serial face mask and saliva samples. These serial measurements and both CPC and water rinses were conducted consecutively in one visit.
Other Names:
  • water rinse

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Control Phase - Primary Endpoint
Time Frame: Single timepoint, ~1 hour
Reduction in viral load by face mask sampling from pre-intervention to 0-15 with CPC versus water rinse control
Single timepoint, ~1 hour
Evaluation Phase - Primary Endpoint
Time Frame: Single timepoint, ~1.5 hours
Reduction in viral load by face mask sampling from pre-intervention to 45-60 minutes versus water rinse control
Single timepoint, ~1.5 hours

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Evaluation Phase - Secondary Endpoint
Time Frame: Single timepoint, ~1 hour
Reduction in viral load by face mask sampling from pre-intervention to 0-15 and15-30 minutes of oral rinse products versus water rinse control
Single timepoint, ~1 hour
Comparative Saliva Reduction
Time Frame: Single timepoint, ~1.5 hours
Reduction in viral load in saliva pre-intervention to 30 and 60 minutes post-intervention.
Single timepoint, ~1.5 hours

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Influence of Speaking
Time Frame: Single timepoint, ~1 hour
Difference in viral load by face mask sampling with speaking versus not speaking
Single timepoint, ~1 hour

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Yingda L Xie, MD, Rutgers University
  • Principal Investigator: David Alland, MD, Rutgers University
  • Principal Investigator: Padmapriya Banada, PhD, Rutgers University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

July 21, 2021

Primary Completion (Actual)

May 24, 2022

Study Completion (Actual)

December 31, 2022

Study Registration Dates

First Submitted

June 16, 2021

First Submitted That Met QC Criteria

June 16, 2021

First Posted (Actual)

June 18, 2021

Study Record Updates

Last Update Posted (Actual)

January 30, 2026

Last Update Submitted That Met QC Criteria

January 28, 2026

Last Verified

January 1, 2026

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

Individual participant data that underlie the results reported in this article, after deidentification (text, tables, figures, and appendices)

IPD Sharing Time Frame

Beginning 3 months and ending 5 years following article publication

IPD Sharing Access Criteria

Researchers who provide a methodologically sound proposal

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL
  • SAP
  • ANALYTIC_CODE

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

Yes

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Covid19

Clinical Trials on Mouthwash Product

Subscribe